- Home
- ALIT vs AXSM Comparison
ALIT vs AXSM Comparison
Compare ALIT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALIT
- AXSM
- Stock Information
- Founded
- ALIT 2017
- AXSM 2012
- Country
- ALIT United States
- AXSM United States
- Employees
- ALIT N/A
- AXSM N/A
- Industry
- ALIT Business Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- ALIT Consumer Discretionary
- AXSM Health Care
- Exchange
- ALIT Nasdaq
- AXSM Nasdaq
- Market Cap
- ALIT 3.5B
- AXSM 4.2B
- IPO Year
- ALIT N/A
- AXSM 2015
- Fundamental
- Price
- ALIT $6.82
- AXSM $137.75
- Analyst Decision
- ALIT Strong Buy
- AXSM Strong Buy
- Analyst Count
- ALIT 9
- AXSM 14
- Target Price
- ALIT $10.61
- AXSM $158.93
- AVG Volume (30 Days)
- ALIT 6.6M
- AXSM 1.2M
- Earning Date
- ALIT 02-20-2025
- AXSM 02-18-2025
- Dividend Yield
- ALIT 1.17%
- AXSM N/A
- EPS Growth
- ALIT N/A
- AXSM N/A
- EPS
- ALIT N/A
- AXSM N/A
- Revenue
- ALIT $2,332,000,000.00
- AXSM $385,693,000.00
- Revenue This Year
- ALIT $4.80
- AXSM $45.18
- Revenue Next Year
- ALIT $4.09
- AXSM $65.22
- P/E Ratio
- ALIT N/A
- AXSM N/A
- Revenue Growth
- ALIT N/A
- AXSM 42.53
- 52 Week Low
- ALIT $6.15
- AXSM $64.11
- 52 Week High
- ALIT $10.38
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- ALIT 51.15
- AXSM 74.55
- Support Level
- ALIT $6.52
- AXSM $124.04
- Resistance Level
- ALIT $7.66
- AXSM $130.52
- Average True Range (ATR)
- ALIT 0.24
- AXSM 5.78
- MACD
- ALIT 0.03
- AXSM 1.11
- Stochastic Oscillator
- ALIT 31.43
- AXSM 96.07
About ALIT Alight Inc.
Alight Inc is a provider of integrated, cloud-based human capital solutions that empower clients and employees to manage health, wealth and HR needs. Geographically, the company generates a majority of its revenue from the United States.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.